| Literature DB >> 30017354 |
Luwen Wang1, Ju Gao1, Jingyi Liu1, Sandra L Siedlak1, Sandy Torres1, Hisashi Fujioka2, Mikayla L Huntley1, Yinfei Jiang1, Haiyan Ji1, Tingxiang Yan1, Micah Harland1, Pichet Termsarasab1, Sophia Zeng1, Zhen Jiang1, Jingjing Liang3, George Perry4, Charles Hoppel5, Cheng Zhang6, Hu Li6, Xinglong Wang7.
Abstract
Skeletal muscles undergo atrophy in response to diseases and aging. Here we report that mitofusin 2 (Mfn2) acts as a dominant suppressor of neuromuscular synaptic loss to preserve skeletal muscles. Mfn2 is reduced in spinal cords of transgenic SOD1G93A and aged mice. Through preserving neuromuscular synapses, increasing neuronal Mfn2 prevents skeletal muscle wasting in both SOD1G93A and aged mice, whereas deletion of neuronal Mfn2 produces neuromuscular synaptic dysfunction and skeletal muscle atrophy. Neuromuscular synaptic loss after sciatic nerve transection can also be alleviated by Mfn2. Mfn2 coexists with calpastatin largely in mitochondria-associated membranes (MAMs) to regulate its axonal transport. Genetic inactivation of calpastatin abolishes Mfn2-mediated protection of neuromuscular synapses. Our results suggest that, as a potential key component of a novel and heretofore unrecognized mechanism of cytoplasmic protein transport, Mfn2 may play a general role in preserving neuromuscular synapses and serve as a common therapeutic target for skeletal muscle atrophy.Entities:
Keywords: Mfn2; amyotrophic lateral sclerosis; axonal transport; calpastatin; mitochondria; mitochondria-associated membranes; nerve injury; neuromuscular synapse; sarcopenia; skeletal muscle atrophy
Mesh:
Substances:
Year: 2018 PMID: 30017354 PMCID: PMC6125186 DOI: 10.1016/j.cmet.2018.06.011
Source DB: PubMed Journal: Cell Metab ISSN: 1550-4131 Impact factor: 27.287